Go Pro
NASDAQ:JBIO

Jade Biosciences Q1 2026 Earnings Report

Jade Biosciences logo
$17.89 -1.25 (-6.53%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$17.90 +0.01 (+0.06%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jade Biosciences EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.52
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Jade Biosciences Earnings Headlines

Jade Biosciences (NASDAQ:JBIO) Stock Rating Lowered by Wall Street Zen
Jade Biosciences to Participate in Upcoming Conferences
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Jade Biosciences: Duration Is The Real Product
Jade Biosciences Inc JBIO
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates. As an early-stage biotechnology company, its programs remain subject to development, regulatory and clinical risks, and the timing of potential product launches is uncertain.

View Jade Biosciences Profile